Pacific Biosciences Of California (PACB) Non-Current Deffered Revenue (2011 - 2026)

Pacific Biosciences Of California's Non-Current Deffered Revenue history runs 16 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 39.3% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $3.6 million (down 39.3% YoY), while the FY2025 annual figure was $3.9 million, down 33.41% from the prior year.
• Non-Current Deffered Revenue was $3.6 million for Q1 2026 at Pacific Biosciences Of California, down from $3.9 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $25.2 million in Q1 2022 to a low of $1.8 million in Q3 2022.
• Historically, Non-Current Deffered Revenue has averaged $5.6 million across 5 years, with a median of $5.1 million in 2023.
• Biggest YoY gain for Non-Current Deffered Revenue was 342.91% in 2022; the steepest drop was 92.84% in 2022.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $1.8 million in 2022, then jumped by 208.25% to $5.5 million in 2023, then gained by 6.69% to $5.9 million in 2024, then sank by 33.41% to $3.9 million in 2025, then slipped by 9.54% to $3.6 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $3.6 million (Q1 2026), $3.9 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.